Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

PMID:
30355724
2.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

3.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM.

Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.

4.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

5.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22. Erratum in: J Clin Invest. 2018 Oct 1;128(10):4743.

6.

As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid.

Pavlova NN, Hui S, Ghergurovich JM, Fan J, Intlekofer AM, White RM, Rabinowitz JD, Thompson CB, Zhang J.

Cell Metab. 2018 Feb 6;27(2):428-438.e5. doi: 10.1016/j.cmet.2017.12.006. Epub 2018 Jan 11.

7.

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME.

Cancer Discov. 2017 Aug;7(8):868-883. doi: 10.1158/2159-8290.CD-16-1032. Epub 2017 Apr 13.

8.

L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH.

Intlekofer AM, Wang B, Liu H, Shah H, Carmona-Fontaine C, Rustenburg AS, Salah S, Gunner MR, Chodera JD, Cross JR, Thompson CB.

Nat Chem Biol. 2017 May;13(5):494-500. doi: 10.1038/nchembio.2307. Epub 2017 Mar 6.

9.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Shih AH, Meydan C, Shank K, Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM, Knapp K, Glass J, Travins J, Straley K, Gliser C, Mason CE, Yen K, Thompson CB, Melnick A, Levine RL.

Cancer Discov. 2017 May;7(5):494-505. doi: 10.1158/2159-8290.CD-16-1049. Epub 2017 Feb 13.

10.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

11.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

12.

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.

He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL.

Blood. 2016 Jun 16;127(24):3004-14. doi: 10.1182/blood-2015-08-664649. Epub 2016 Mar 10.

13.

Hypoxia Induces Production of L-2-Hydroxyglutarate.

Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, Rustenburg AS, Grinaway PB, Chodera JD, Cross JR, Thompson CB.

Cell Metab. 2015 Aug 4;22(2):304-11. doi: 10.1016/j.cmet.2015.06.023. Epub 2015 Jul 23.

14.

Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.

Mancebo SE, Smith JR, Intlekofer AM, Zelenetz AD, Myskowski PL.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e113-5. doi: 10.1016/j.clml.2014.11.003. Epub 2014 Nov 18. No abstract available.

PMID:
25499623
15.

Precision therapy for lymphoma--current state and future directions.

Intlekofer AM, Younes A.

Nat Rev Clin Oncol. 2014 Oct;11(10):585-96. doi: 10.1038/nrclinonc.2014.137. Epub 2014 Aug 19. Review.

PMID:
25135367
16.

From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Intlekofer AM, Younes A.

Int J Hematol. 2014 Mar;99(3):249-62. doi: 10.1007/s12185-014-1521-2. Epub 2014 Feb 8. Review.

PMID:
24510453
17.

Induction of sarcomas by mutant IDH2.

Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB.

Genes Dev. 2013 Sep 15;27(18):1986-98. doi: 10.1101/gad.226753.113.

18.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

19.

Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection.

Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, Wherry EJ.

Nat Immunol. 2011 May 29;12(7):663-71. doi: 10.1038/ni.2046.

20.

Cutting edge: Lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin.

Kinjyo I, Gordon SM, Intlekofer AM, Dowdell K, Mooney EC, Caricchio R, Grupp SA, Teachey DT, Rao VK, Lindsten T, Reiner SL.

J Immunol. 2010 Dec 15;185(12):7151-5. doi: 10.4049/jimmunol.1003193. Epub 2010 Nov 12.

21.

Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche.

Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner SL.

J Immunol. 2010 Nov 1;185(9):4988-92. doi: 10.4049/jimmunol.1002042. Epub 2010 Oct 8.

22.

A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection.

Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ.

Immunity. 2009 Aug 21;31(2):309-20. doi: 10.1016/j.immuni.2009.06.019. Epub 2009 Aug 6.

23.

Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A.

Yashiro-Ohtani Y, He Y, Ohtani T, Jones ME, Shestova O, Xu L, Fang TC, Chiang MY, Intlekofer AM, Blacklow SC, Zhuang Y, Pear WS.

Genes Dev. 2009 Jul 15;23(14):1665-76. doi: 10.1101/gad.1793709.

24.

Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin.

Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL.

Science. 2008 Jul 18;321(5887):408-11. doi: 10.1126/science.1159806.

25.

Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.

Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, Northrop JK, Shen H, Wherry EJ, Reiner SL.

J Exp Med. 2007 Sep 3;204(9):2015-21. Epub 2007 Aug 13.

26.

Asymmetric T lymphocyte division in the initiation of adaptive immune responses.

Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A, Longworth SA, Vinup KE, Mrass P, Oliaro J, Killeen N, Orange JS, Russell SM, Weninger W, Reiner SL.

Science. 2007 Mar 23;315(5819):1687-91. Epub 2007 Mar 1.

27.

Epigenetic and transcriptional programs lead to default IFN-gamma production by gammadelta T cells.

Chen L, He W, Kim ST, Tao J, Gao Y, Chi H, Intlekofer AM, Harvey B, Reiner SL, Yin Z, Flavell RA, Craft J.

J Immunol. 2007 Mar 1;178(5):2730-6. Erratum in: J Immunol. 2007 Apr 15;178(8):5401.

28.

Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiation.

Jenkinson SR, Intlekofer AM, Sun G, Feigenbaum L, Reiner SL, Bosselut R.

J Exp Med. 2007 Feb 19;204(2):267-72. Epub 2007 Feb 12.

29.

Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation.

Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL.

J Immunol. 2006 Dec 1;177(11):7515-9.

30.

Not-so-great expectations: re-assessing the essence of T-cell memory.

Intlekofer AM, Wherry EJ, Reiner SL.

Immunol Rev. 2006 Jun;211:203-13. Review.

PMID:
16824129
31.

Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, Mullen AC, Gasink CR, Kaech SM, Miller JD, Gapin L, Ryan K, Russ AP, Lindsten T, Orange JS, Goldrath AW, Ahmed R, Reiner SL.

Nat Immunol. 2005 Dec;6(12):1236-44. Epub 2005 Nov 6. Erratum in: Nat Immunol. 2006 Jan;7(1):113.

PMID:
16273099

Supplemental Content

Loading ...
Support Center